TRILLIUM THERAPEUTICS INC. 2,750,000 Common Shares 3,250,000 Series II First Preferred Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 26th, 2017 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
Trillium Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement with Cowen and Company, LLC (“Cowen”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Cowen is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of common shares, no par value per share, of the Company (“Common Shares”) and Series II Non-Voting Convertible First Preferred Shares, no par value (the “Series II First Preferred Shares”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 412
